#2862
Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction:
The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Martin C,
Mitrache M,
Nitipir C,
Terzea D,
Stroescu C,
Keywords:
pulmonary neuroendocrine tumors,
pituitary macroadenoma,
#80
Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction:
Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference:
7th Annual ENETSConcerence (2010)
Presenting Author:
Kassem S
Authors:
Kassem S,
Gross D,
Doviner V,
Dresner-Pollak R,
Keywords:
pituitary carcinoma,
peptide receptor radionuclide therapy,
acromegaly,
